Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload

Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload

Selective SGLT2 inhibition reduces the risk of worsening heart failure and cardiovascular death in patients with existing heart failure, irrespective of diabetic status. We aimed to investigate the effects of dual SGLT1/2 inhibition, using sotagliflozin, on cardiac outcomes in normal diet (ND) and h...

Full description

Bibliographic Details
Main Authors:	Sophia L. Young, Lydia Ryan, Thomas P. Mullins, Melanie Flint, Sarah E. Steane, Sarah L. Walton, Helle Bielefeldt-Ohmann, David A. Carter, Melissa E. Reichelt, Linda A. Gallo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-09-01
Series:	Frontiers in Physiology
Subjects:	energy expenditure energy intake proximal tubular cell damage cardiac hypertrophy cardiovasclar disease heart failure
Online Access:	https://www.frontiersin.org/articles/10.3389/fphys.2021.738594/full

Similar Items

Inosine: A bioactive metabolite with multimodal actions in human diseases
by: In Soo Kim, et al.
Published: (2022-11-01)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
by: Natalia G. Vallianou, et al.
Published: (2021-06-01)

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
by: Chiara Maria Assunta Cefalo, et al.
Published: (2019-02-01)

Premature stroke and cardiovascular risk in primary Sjögren's syndrome
by: Clara L. Zippel, et al.
Published: (2022-12-01)

Editorial: Gut permeability-related endotoxemia and cardiovascular disease: A new clinical challenge
by: Francesco Violi, et al.
Published: (2023-03-01)

Editorial: Methods and application in cardiovascular and smooth muscle pharmacology: 2021
by: Ahmed F. El-Yazbi, et al.
Published: (2022-10-01)

Editorial: Biomaterials in cardiovascular research: Models, methods, and therapies
by: Yingfei Xue, et al.
Published: (2023-01-01)

Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats
by: Peng Zhong, et al.
Published: (2023-11-01)

Editorial: Bioengineering and biotechnology approaches in cardiovascular regenerative medicine, volume II
by: Mehdi Salar Amoli, et al.
Published: (2024-02-01)

Editorial: Peritoneal dialysis: Recent advances and state of the art
by: John Larkin, et al.
Published: (2023-04-01)

Hypertension and human immunodeficiency virus: A paradigm for epithelial sodium channels?
by: Katongo H. Mutengo, et al.
Published: (2022-08-01)

Prognostic Impact of Metabolic Syndrome in Patients With Heart Failure: A Meta-Analysis of Observational Studies
by: Zhuo-Ming Huang, et al.
Published: (2021-06-01)

Editorial: RNA Biology in Cardiovascular Disease
by: Maarten M. G. van den Hoogenhof, et al.
Published: (2021-10-01)

Gene Lifestyle Interactions With Relation to Obesity, Cardiometabolic, and Cardiovascular Traits Among South Asians
by: Shafqat Ahmad, et al.
Published: (2019-04-01)

Baseline and Cumulative Blood Pressure in Predicting the Occurrence of Cardiovascular Events
by: Yingting Zuo, et al.
Published: (2021-09-01)

Editorial: Gut Microbiota and Inflammation: Relevance in Cancer and Cardiovascular Disease
by: Cinzia Parolini, et al.
Published: (2020-12-01)

Gene Expression Profiling Reveals the Shared and Distinct Transcriptional Signatures in Human Lung Epithelial Cells Infected With SARS-CoV-2, MERS-CoV, or SARS-CoV: Potential Implications in Cardiovascular Complications of COVID-19
by: Prabhash Kumar Jha, et al.
Published: (2021-01-01)

Sotagliflozin, an inhibitor of sodium–glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus
by: Mirella Czapska, et al.
Published: (2018-12-01)

Sotagliflozin, an inhibitor of sodium–glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus
by: Mirella Czapska, et al.
Published: (2018-12-01)

10 Pre-clinical studies of sotagliflozin in hypertrophic cardiomyopathy
by: Rebecca Taichman, et al.
Published: (2024-04-01)

A review of sotagliflozin for use in type 1 diabetes
by: Wesley Nuffer, et al.
Published: (2019-11-01)

Direct cardiac effects of SGLT2 inhibitors
by: Sha Chen, et al.
Published: (2022-03-01)

SGLT1 Knockdown Attenuates Cardiac Fibroblast Activation in Diabetic Cardiac Fibrosis
by: Hui Lin, et al.
Published: (2021-06-01)

SOTAGLIFLOZIN SIGNIFICANTLY REDUCES CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN THE SCORED TRIAL
by: Deepak L. Bhatt, et al.
Published: (2023-03-01)

The journey from gene knockout to clinical medicine: telotristat and sotagliflozin
by: Rendell MS
Published: (2019-03-01)

SGLT2 inhibitors and the cardiac rhythm: unraveling the connections
by: Aritra Paul, et al.
Published: (2024-01-01)

Dual versus single energy cardiac CT to measure extracellular volume in cardiac amyloidosis: correlations with cardiac MRI
by: Anahita Tavoosi, et al.
Published: (2023-02-01)

Managing heart failure in diabetics with dual acting sotagliflozin—A review
by: Kushal Seni, et al.
Published: (2023-12-01)

Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
by: Inho Kim, et al.
Published: (2023-06-01)

Survey effect of energy therapy method on anxiety and incidence of cardiac Dysrhythmia inpatients under cardiac catheterization
by: M Zolfaghari, et al.
Published: (2001-05-01)

Survey effect of energy therapy method on anxiety and incidence of cardiac Dysrhythmia inpatients under cardiac catheterization
by: M. Zolfaghari, et al.
Published: (2001-05-01)

Editorial: Novel Concepts in Cardiac Energy Metabolism: From Biology to Disease
by: Thomas Pulinilkunnil, et al.
Published: (2019-07-01)

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
by: Lucia Scisciola, et al.
Published: (2023-02-01)

PVDF Energy Harvester for Prolonging the Battery Life of Cardiac Pacemakers
by: Christopher Hu, et al.
Published: (2022-07-01)

Transplantation of Human Pluripotent Stem Cell-Derived Cardiomyocytes for Cardiac Regenerative Therapy
by: Sophia E. Silver, et al.
Published: (2021-11-01)

The Impact of Isolation Measures Due to COVID-19 on Energy Intake and Physical Activity Levels in Australian University Students
by: Linda A. Gallo, et al.
Published: (2020-06-01)

Effect of lunging exercise program with Pessoa training aid on cardiac physical conditioning predictors in adult horses
by: R.F. Siqueira, et al.
Published: (2023-07-01)

Regulation of Cardiac Fibroblast GLS1 Expression by Scleraxis
by: Sikta Chattopadhyaya, et al.
Published: (2022-04-01)

Author Correction: Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
by: Inho Kim, et al.
Published: (2024-01-01)

Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
by: Powell DR, et al.
Published: (2015-02-01)